BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 37897866)

  • 1. Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.
    Helal C; Pobel C; Bayle A; Vasseur D; Nicotra C; Blanc-Durand F; Naoun N; Bernard-Tessier A; Patrikidou A; Colomba E; Flippot R; Fuerea A; Auger N; Ngo Camus M; Besse B; Lacroix L; Rouleau E; Ponce S; Italiano A; Loriot Y
    Eur J Cancer; 2023 Dec; 195():113368. PubMed ID: 37897866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical utility of circulating tumor DNA sequencing with a large panel: a National Center for Precision Medicine (PRISM) study.
    Bayle A; Belcaid L; Aldea M; Vasseur D; Peyraud F; Nicotra C; Geraud A; Sakkal M; Seknazi L; Cerbone L; Blanc-Durand F; Hadoux J; Mosele F; Tagliamento M; Bernard-Tessier A; Verret B; Smolenschi C; Clodion R; Auger N; Romano PM; Gazzah A; Camus MN; Micol J; Caron O; Hollebecque A; Loriot Y; Besse B; Lacroix L; Rouleau E; Ponce S; Soria JC; Barlesi F; Andre F; Italiano A
    Ann Oncol; 2023 Apr; 34(4):389-396. PubMed ID: 36709039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular characterization of ctDNA from Chinese patients with advanced gastric adenocarcinoma reveals actionable alterations for targeted and immune therapy.
    Zhang M; Qi C; Wang Z; Chen H; Zhao X; Zhang X; Zhou Y; Gao C; Bai Y; Jia S; Ji J
    J Mol Med (Berl); 2021 Sep; 99(9):1311-1321. PubMed ID: 34057552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
    Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
    PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
    Agarwal N; Pal SK; Hahn AW; Nussenzveig RH; Pond GR; Gupta SV; Wang J; Bilen MA; Naik G; Ghatalia P; Hoimes CJ; Gopalakrishnan D; Barata PC; Drakaki A; Faltas BM; Kiedrowski LA; Lanman RB; Nagy RJ; Vogelzang NJ; Boucher KM; Vaishampayan UN; Sonpavde G; Grivas P
    Cancer; 2018 May; 124(10):2115-2124. PubMed ID: 29517810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated longitudinal circulating tumor DNA profiling predicts immunotherapy response of metastatic urothelial carcinoma in the POLARIS-03 trial.
    Zang J; Zhang R; Jin D; Xie F; Shahatiaili A; Wu G; Zhang Y; Zhao Z; Du P; Jia S; Chen H; Zhuang G
    J Pathol; 2023 Oct; 261(2):198-209. PubMed ID: 37584165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.
    Vandekerkhove G; Lavoie JM; Annala M; Murtha AJ; Sundahl N; Walz S; Sano T; Taavitsainen S; Ritch E; Fazli L; Hurtado-Coll A; Wang G; Nykter M; Black PC; Todenhöfer T; Ost P; Gibb EA; Chi KN; Eigl BJ; Wyatt AW
    Nat Commun; 2021 Jan; 12(1):184. PubMed ID: 33420073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of mutation patterns and circulating tumour DNA-derived prognostic markers in advanced breast cancer patients.
    Liao H; Zhang J; Zheng T; Liu X; Zhong J; Shao B; Dong X; Wang X; Du P; King BL; Jia S; Yu J; Li H
    J Transl Med; 2022 May; 20(1):211. PubMed ID: 35562750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA.
    Thompson JC; Yee SS; Troxel AB; Savitch SL; Fan R; Balli D; Lieberman DB; Morrissette JD; Evans TL; Bauml J; Aggarwal C; Kosteva JA; Alley E; Ciunci C; Cohen RB; Bagley S; Stonehouse-Lee S; Sherry VE; Gilbert E; Langer C; Vachani A; Carpenter EL
    Clin Cancer Res; 2016 Dec; 22(23):5772-5782. PubMed ID: 27601595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of Somatic Genomic Alterations Between Tissue Genomics and ctDNA Employing Next-Generation Sequencing: Analysis of Lung and Gastrointestinal Cancers.
    Toor OM; Ahmed Z; Bahaj W; Boda U; Cummings LS; McNally ME; Kennedy KF; Pluard TJ; Hussain A; Subramanian J; Masood A
    Mol Cancer Ther; 2018 May; 17(5):1123-1132. PubMed ID: 29500272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profiling of Chinese patients with urothelial carcinoma.
    Yang B; Zhao X; Wan C; Ma X; Niu S; Guo A; Wang J; Wang J; Sun D; Jiao S
    BMC Cancer; 2021 Feb; 21(1):162. PubMed ID: 33588785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
    Tarasova VD; Tsai J; Masannat J; Hernandez Prera JC; Hallanger Johnson J; Veloski C; Agosto Salgado S; McIver B; Drusbosky LM; Chung CH
    Thyroid; 2024 Feb; 34(2):197-205. PubMed ID: 37962267
    [No Abstract]   [Full Text] [Related]  

  • 15. Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.
    Tukachinsky H; Madison RW; Chung JH; Gjoerup OV; Severson EA; Dennis L; Fendler BJ; Morley S; Zhong L; Graf RP; Ross JS; Alexander BM; Abida W; Chowdhury S; Ryan CJ; Fizazi K; Golsorkhi T; Watkins SP; Simmons A; Loehr A; Venstrom JM; Oxnard GR
    Clin Cancer Res; 2021 Jun; 27(11):3094-3105. PubMed ID: 33558422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary Molecular Pathology for Patients with Newly Diagnosed Urothelial Bladder Cancer.
    Zhang R; Zang J; Xie F; Zhang Y; Wang Y; Jing Y; Zhang Y; Chen Z; Shahatiaili A; Cai MC; Zhao Z; Du P; Jia S; Zhuang G; Chen H
    J Urol; 2021 Oct; 206(4):873-884. PubMed ID: 34061567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of Circulating Tumor DNA in Identifying Somatic Mutations and Tracking Tumor Evolution in Patients With Non-small Cell Lung Cancer.
    Roosan MR; Mambetsariev I; Pharaon R; Fricke J; Husain H; Reckamp KL; Koczywas M; Massarelli E; Bild AH; Salgia R
    Chest; 2021 Sep; 160(3):1095-1107. PubMed ID: 33878340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.
    Bacon JVW; Annala M; Soleimani M; Lavoie JM; So A; Gleave ME; Fazli L; Wang G; Chi KN; Kollmannsberger CK; Wyatt AW; Nappi L
    Clin Genitourin Cancer; 2020 Aug; 18(4):322-331.e2. PubMed ID: 32046920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tailored molecular profiling programme for children with cancer to identify clinically actionable genetic alterations.
    George SL; Izquierdo E; Campbell J; Koutroumanidou E; Proszek P; Jamal S; Hughes D; Yuan L; Marshall LV; Carceller F; Chisholm JC; Vaidya S; Mandeville H; Angelini P; Wasti A; Bexelius T; Thway K; Gatz SA; Clarke M; Al-Lazikani B; Barone G; Anderson J; Tweddle DA; Gonzalez D; Walker BA; Barton J; Depani S; Eze J; Ahmed SW; Moreno L; Pearson A; Shipley J; Jones C; Hargrave D; Jacques TS; Hubank M; Chesler L
    Eur J Cancer; 2019 Nov; 121():224-235. PubMed ID: 31543384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early On-treatment Circulating Tumor DNA Measurements and Response to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer.
    Tolmeijer SH; van Wilpe S; Geerlings MJ; von Rhein D; Smilde TJ; Kloots ISH; Westdorp H; Coskuntürk M; Oving IM; van Ipenburg JA; van der Heijden AG; Hofste T; Weiss MM; Schalken JA; Gerritsen WR; Ligtenberg MJL; Mehra N
    Eur Urol Oncol; 2024 Apr; 7(2):282-291. PubMed ID: 37673768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.